Sonodynamic Therapy for Malignant Glioma Using 220-kHz Transcranial Magnetic Resonance Imaging-Guided Focused Ultrasound and 5-Aminolevulinic acid.
Animals
Brain
/ diagnostic imaging
Brain Neoplasms
/ therapy
Cell Line, Tumor
Cells, Cultured
Combined Modality Therapy
/ methods
Disease Models, Animal
Female
Glioma
/ therapy
Levulinic Acids
/ therapeutic use
Magnetic Resonance Imaging
/ methods
Radiology, Interventional
/ methods
Rats
Rats, Inbred F344
Ultrasonic Therapy
/ methods
Aminolevulinic Acid
5-Aminolevulinic acid
Malignant glioma
Sonodynamic therapy
Transcranial magnetic resonance imaging-guided focused ultrasound
Journal
Ultrasound in medicine & biology
ISSN: 1879-291X
Titre abrégé: Ultrasound Med Biol
Pays: England
ID NLM: 0410553
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
22
02
2018
revised:
07
09
2018
accepted:
11
10
2018
pubmed:
14
12
2018
medline:
30
7
2019
entrez:
8
12
2018
Statut:
ppublish
Résumé
Sonodynamic therapy (SDT) is used to treat various malignancies and can be applied to brain tumors using a transcranial magnetic resonance imaging-guided focused ultrasound (TcMRgFUS) device. This study investigated the efficacy of 220-kHz TcMRgFUS combined with 5-aminolevulinic acid (5-ALA) on malignant glioma in vitro and in vivo. F98 cells were irradiated with focused ultrasound (FUS) (4000 J, 20 W, 240 s, 100% duty cycle, target medium temperature <40°C) after treatment with 200 µg/mL 5-ALA, and cell viability and apoptosis were evaluated with the water-soluble tetrazolium-1 assay, triple fluorescent staining and Western blot analysis 20 h later. The anti-tumor effects of 5-ALA combined with FUS (500 J, 18 W, 30 s, 100% duty cycle, 10 repeats, target tissue temperature ≤42°C) were assessed on the basis of changes in tumor volume determined by MRI and histopathological analysis before and after treatment. The FUS/5-ALA combination reduced cell viability by inducing apoptosis and suppressed tumor proliferation and invasion as well as angiogenesis in vivo, while causing minimal damage to normal brain tissue. SDT with 220-kHz TcMRgFUS and 5-ALA can be safely used for the treatment of malignant glioma.
Identifiants
pubmed: 30522817
pii: S0301-5629(18)30467-8
doi: 10.1016/j.ultrasmedbio.2018.10.016
pii:
doi:
Substances chimiques
Levulinic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
526-538Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.